Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
Status:
Not yet recruiting
Trial end date:
2025-11-05
Target enrollment:
Participant gender:
Summary
This study is a multi-center, open-label, single-arm, non-randomized phase II clinical study
in order to evaluate the safety and efficacy of Orelabrutinib, Fludarabine, Cyclophosphamide,
and Obinutuzumab (GA-101) (oFCG) in the Treatment of Newly Diagnosed Chronic Lymphocytic
Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University